Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial

Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial

In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhal...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mustafa Erelel, Mert Kaskal, Ozlem Akbal-Dagistan, Halim Issever, Ahmet Serhan Dagistanli, Hilal Balkanci, Merve Sinem Oguz, Aygun Qarayeva, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Ali Yagiz Uresin, Ahmet Ogul Araman, Alpay Medetalibeyoglu, Tufan Tukek, Mustafa Oral Oncul, Ayca Yildiz-Pekoz
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
COVID-19
low-molecular-weight heparin
soft-mist inhaler
pulmonary
anti-coagulant
Pharmacy and materia medica
RS1-441
Acceso en línea:https://doaj.org/article/19984ebfb6c54daa9d40a18bd3016123
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/19984ebfb6c54daa9d40a18bd3016123

Ejemplares similares